Tirzepatide

Status

FDA-approved. Approved since 2022 (Mounjaro, type 2 diabetes) and 2023 (Zepbound, weight management); an obstructive sleep apnea indication followed in 2024.

What it is

A dual agonist: one 39-amino-acid peptide that engages both the GLP-1 and GIP receptors. The GIP arm is the difference from semaglutide, and is the reason the two drugs are not interchangeable copies of each other.

What published research measured

The SURPASS program studied type 2 diabetes and the SURMOUNT program studied weight management; SURMOUNT-1 (NEJM 2022) enrolled 2,539 adults with obesity, or overweight with a comorbidity, without diabetes, over 72 weeks. SURMOUNT-OSA studied sleep apnea outcomes.

Source

FDA prescribing information (Mounjaro, Zepbound); SURMOUNT-1, NEJM 2022 Primary source

Sources

• FDA prescribing information (Mounjaro, Zepbound); SURMOUNT-1, NEJM 2022
• SURMOUNT-1, PubMed 35658024
• Zepbound (weekly) prescribing information
• Mounjaro US prescribing information
• SURMOUNT-1 registry record NCT04184622